GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rize Oncology Inc (XCNQ:RIZE) » Definitions » Current Accrued Expense

Rize Oncology (XCNQ:RIZE) Current Accrued Expense : C$0.00 Mil (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Rize Oncology Current Accrued Expense?

Rize Oncology's Current Accrued Expense for the quarter that ended in Dec. 2024 was C$0.00 Mil.


Rize Oncology Current Accrued Expense Historical Data

The historical data trend for Rize Oncology's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rize Oncology Current Accrued Expense Chart

Rize Oncology Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Current Accrued Expense
- - - - -

Rize Oncology Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Rize Oncology Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.


Rize Oncology Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Rize Oncology's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Rize Oncology Business Description

Traded in Other Exchanges
Address
301-1665 Ellis Street, c/o Pushor Mitchell LLP, Kelowna, BC, CAN, V1Y 2B3
Rize Oncology Inc is is a biopharmaceutical company. The company is focused on the development of high-efficiency precision gene editing for human therapeutics applications. The company is also engaged in oncology, particularly soft tissue sarcoma, introduced by the recent exclusive licensing of STS-201, delivering small molecules targeting soft tissue sarcoma and other cancers.
Executives
William James Garner 10% Security Holder, Director
Andre Pereira Fraga Figueiredo Director

Rize Oncology Headlines

No Headlines